

**GEOVAX LABS, INC.**  
**Condensed Consolidated Statements of Operations Information**  
(amounts in thousands, except per share data)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2018	2017	2018	2017
Grant and collaboration revenue	\$ 349	\$ 248	\$ 664	\$ 896
Operating expenses:				
Research and development	557	498	1,417	1,568
General and administrative	459	340	1,175	985
	<u>1,016</u>	<u>838</u>	<u>2,592</u>	<u>2,553</u>
Loss from operations	(667)	(590)	(1,928)	(1,657)
Other income (expense), net	-	1	2	3
Net loss	<u>\$ (667)</u>	<u>\$ (589)</u>	<u>\$ (1,926)</u>	<u>\$ (1,654)</u>
Loss per common share	<u>\$ (0.00)</u>	<u>\$ (0.01)</u>	<u>\$ (0.01)</u>	<u>\$ (0.03)</u>

**GEOVAX LABS, INC.**  
**Condensed Consolidated Balance Sheet Information**  
(amounts in thousands)

	Sep. 30, 2018	Dec. 31, 2017
Assets:		
Cash and cash equivalents	\$ 511	\$ 313
Other current assets	85	135
Total current assets	<u>596</u>	<u>448</u>
Property, net	16	31
Other assets	11	11
Total assets	<u>\$ 623</u>	<u>\$ 490</u>
Liabilities and stockholders' equity (deficiency)		
Current liabilities	\$ 1,305	\$ 811
Note payable, net of current portion	42	-
Stockholders' equity (deficiency)	(724)	(321)
Total liabilities and stockholders' equity (deficiency)	<u>\$ 623</u>	<u>\$ 490</u>
Common shares outstanding	178,403	106,737